{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:35:17Z","timestamp":1794123317106,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NuProbe USA, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whole exome sequencing\u00a0(WES) is used to identify mutations in a patient\u2019s tumor DNA that are predictive of tumor behavior, including the likelihood of response or resistance to cancer\u00a0therapy. WES has a mutation limit of detection (LoD) at variant allele frequencies (VAF) of 5%. Putative mutations called at\u2009\u2264\u20095% VAF are frequently due to sequencing errors, therefore reporting these subclonal mutations incurs risk of significant false positives. Here we performed\u2009~\u20091000\u2009\u00d7\u2009WES on fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue biopsy samples from a non-small cell lung cancer patient, and identified 226 putative mutations at between 0.5 and 5% VAF. Each variant was then tested using NuProbe NGSure, to confirm the original WES calls. NGSure utilizes Blocker Displacement Amplification to first enrich the allelic fraction of the mutation and then uses Sanger sequencing to determine mutation identity. Results showed that 52% of the 226 (117) putative variants were disconfirmed, among which 2% (5) putative variants were found to be misidentified in WES. In the 66 cancer-related variants, the disconfirmed rate was 82% (54\/66). This data demonstrates Blocker Displacement Amplification allelic enrichment coupled with Sanger sequencing can be used to confirm putative mutations\u2009\u2264\u20095% VAF. By implementing this method, next-generation sequencing can reliably report low-level variants at a high sensitivity, without the cost of high sequencing depth.<\/jats:p>","DOI":"10.1038\/s41598-021-91142-1","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:08:04Z","timestamp":1622628484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Confirming putative variants at\u2009\u2264\u20095% allele frequency using allele enrichment and Sanger sequencing"],"prefix":"10.1038","volume":"11","author":[{"given":"Yan Helen","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa Y.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"7261","key":"91142_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature08250","volume":"461","author":"SB Ng","year":"2009","unstructured":"Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461(7261), 272\u2013276 (2009).","journal-title":"Nature"},{"issue":"6","key":"91142_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1586\/14737159.2015.1039516","volume":"15","author":"M Tetreault","year":"2015","unstructured":"Tetreault, M. et al. Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities. Exp. Rev. Mol. Diagn. 15(6), 749\u2013760 (2015).","journal-title":"Exp. Rev. Mol. Diagn."},{"key":"91142_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"91142_CR4","doi-asserted-by":"crossref","unstructured":"Lier, A. et al. Validating comprehensive next-generation sequencing results for precision oncology: The NCT\/DKTK molecularly aided stratification for tumor eradication research experience. JCO Precis. Oncol., 1\u201313 (2018).","DOI":"10.1200\/PO.18.00171"},{"key":"91142_CR5","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1073\/pnas.1418631112","volume":"112","author":"A Belkadi","year":"2015","unstructured":"Belkadi, A. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc. Natl. Acad. Sci. USA 112, 5473\u20135478 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"91142_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262\u2013269 (2016).","journal-title":"Nat. Med."},{"key":"91142_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926\u2013930 (2018).","journal-title":"Science"},{"key":"91142_CR8","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","volume":"23","author":"MC Schwaederl\u00e9","year":"2017","unstructured":"Schwaederl\u00e9, M. C. et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin. Cancer Res. 23, 5101\u20135111 (2017).","journal-title":"Clin. Cancer Res."},{"key":"91142_CR9","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin. Cancer Res. 23, 5687\u20135695 (2017).","journal-title":"Clin. Cancer Res."},{"key":"91142_CR10","doi-asserted-by":"crossref","unstructured":"Verhein, K. C. et al. Analytical validation of Illumina's TruSight Oncology 500 ctDNA assay [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020. Cancer Res. 80, abstract 3114 (2020)","DOI":"10.1158\/1538-7445.AM2020-3114"},{"key":"91142_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547\u2013555 (2016).","journal-title":"Nat. Biotechnol."},{"key":"91142_CR12","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. USA 109, 14508\u201314513 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"91142_CR13","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1073\/pnas.1418631112","volume":"112","author":"A Belkadi","year":"2015","unstructured":"Belkadi, A. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc. Natl. Acad. Sci USA 112, 5473\u20135478 (2015).","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"91142_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature24286","volume":"550","author":"J Shendure","year":"2017","unstructured":"Shendure, J. et al. DNA sequencing at 40: past, present and future. Nature 550, 345\u2013353 (2017).","journal-title":"Nature"},{"key":"91142_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jmoldx.2016.07.006","volume":"18","author":"W Mu","year":"2016","unstructured":"Mu, W., Lu, H. M., Chen, J., Li, S. & Elliott, A. M. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J. Mol. Diagn. 18, 923\u2013932 (2016).","journal-title":"J. Mol. Diagn."},{"key":"91142_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jmoldx.2015.03.004","volume":"17","author":"LM Baudhuin","year":"2015","unstructured":"Baudhuin, L. M. et al. Confirming variants in next-generation sequencing panel testing by Sanger sequencing. J. Mol. Diagn. 17, 456\u2013461 (2015).","journal-title":"J. Mol. Diagn."},{"key":"91142_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41551-017-0126-5","volume":"1","author":"LR Wu","year":"2017","unstructured":"Wu, L. R., Chen, S. X., Wu, Y., Patel, A. A. & Zhang, D. Y. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification. Nat. Biomed. Eng. 1, 714\u2013723 (2017).","journal-title":"Nat. Biomed. Eng."},{"key":"91142_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41436-020-0897-z","volume":"22","author":"T Gambin","year":"2020","unstructured":"Gambin, T. et al. Low-level parental somatic mosaic SNVs in exomes from a large cohort of trios with diverse suspected Mendelian conditions. Genet. Med. 22, 1768\u20131776 (2020).","journal-title":"Genet. Med."},{"key":"91142_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/2159-8290.CD-17-0745","volume":"8","author":"G Romano","year":"2018","unstructured":"Romano, G. et al. A preexisting rare PIK3CA(E545K) subpopulation confers clinical resistance to MEK plus CDK4\/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 8, 556\u2013567 (2018).","journal-title":"Cancer Discov."},{"key":"91142_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jmoldx.2019.12.007","volume":"22","author":"JA Karolak","year":"2020","unstructured":"Karolak, J. A. et al. Highly sensitive blocker displacement amplification and droplet digital PCR reveal low-level parental FOXF1 somatic mosaicism in families with alveolar capillary dysplasia with misalignment of pulmonary veins. J. Mol. Diagn. 22, 447\u2013456 (2020).","journal-title":"J. Mol. Diagn."},{"key":"91142_CR21","doi-asserted-by":"publisher","first-page":"9043","DOI":"10.1038\/s41598-021-88391-5","volume":"11","author":"LY Cheng","year":"2021","unstructured":"Cheng, L. Y. et al. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci. Rep. 11, 9043 (2021).","journal-title":"Sci. Rep."},{"key":"91142_CR22","doi-asserted-by":"crossref","unstructured":"Song, P., Chen, S.X., Yan, Y.H. et al. Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing. Nat. Biomed. Eng. (2021).","DOI":"10.1038\/s41551-021-00713-0"},{"key":"91142_CR23","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T. et al. Variant review with the integrative genomics viewer. Cancer Res. 77, e31\u2013e34 (2017).","journal-title":"Cancer Res."},{"key":"91142_CR24","doi-asserted-by":"crossref","unstructured":"Scheffler, K., et al. Accuracy improvements in somatic whole-genome small-variant calling with the DRAGEN platform. In Proceedings of the Annual Meeting of the American Association for Cancer Research (2020).","DOI":"10.1158\/1538-7445.AM2020-5463"},{"key":"91142_CR25","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15, e0237802 (2020).","journal-title":"PLoS ONE"},{"key":"91142_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","volume":"61","author":"H Do","year":"2015","unstructured":"Do, H. et al. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin. Chem. 61, 64\u201371 (2015).","journal-title":"Clin. Chem."},{"key":"91142_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40291-014-0115-2","volume":"18","author":"G Chen","year":"2014","unstructured":"Chen, G. et al. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol. Diagn. Ther. 18, 587\u2013593 (2014).","journal-title":"Mol. Diagn. Ther."},{"key":"91142_CR28","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucl. Acids Res. 41, e67 (2013).","journal-title":"Nucl. Acids Res."},{"key":"91142_CR29","unstructured":"Olson, N. D., et al. precisionFDA Truth Challenge V2: Calling variants from short-and long-reads in difficult-to-map regions.\u00a0bioRxiv\u00a0(2020)."},{"key":"91142_CR30","doi-asserted-by":"publisher","first-page":"20222","DOI":"10.1038\/s41598-020-77218-4","volume":"10","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Accuracy and efficiency of germline variant calling pipelines for human genome data. Sci. Rep. 10, 20222 (2020).","journal-title":"Sci. Rep."},{"key":"91142_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1471-2164-15-244","volume":"15","author":"H Xu","year":"2014","unstructured":"Xu, H. et al. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genom. 15, 244 (2014).","journal-title":"BMC Genom."},{"key":"91142_CR32","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604\u20138610 (2011).","journal-title":"Anal. Chem."},{"key":"91142_CR33","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-14-2151","volume":"21","author":"M Watanabe","year":"2015","unstructured":"Watanabe, M. et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin. Cancer Res. 21, 3552\u20133560 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"91142_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrg.2016.145","volume":"18","author":"LA Forsberg","year":"2017","unstructured":"Forsberg, L. A. et al. Mosaicism in health and disease\u2014clones picking up speed. Nat. Rev. Genet. 18(2), 128 (2017).","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"91142_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13073-019-0658-2","volume":"11","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. A clinical survey of mosaic single nucleotide variants in disease-causing genes detected by exome sequencing. Genome Med. 11(1), 48 (2019).","journal-title":"Genome Med."},{"issue":"2","key":"91142_CR36","doi-asserted-by":"publisher","first-page":"e0212708","DOI":"10.1371\/journal.pone.0212708","volume":"14","author":"J Valero-Garcia","year":"2019","unstructured":"Valero-Garcia, J. et al. Earlier relapse detection after allogeneic haematopoietic stem cell transplantation by chimerism assays: digital PCR versus quantitative real-time PCR of insertion\/deletion polymorphisms. PLoS ONE 14(2), e0212708 (2019).","journal-title":"PLoS ONE"},{"issue":"3","key":"91142_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3892\/br.2016.590","volume":"4","author":"GB Stefano","year":"2016","unstructured":"Stefano, G. B. et al. Mitochondrial DNA heteroplasmy in human health and disease. Biomed. Rep. 4(3), 259\u2013262 (2016).","journal-title":"Biomed. Rep."},{"issue":"1","key":"91142_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67686-z","volume":"10","author":"R Maeda","year":"2020","unstructured":"Maeda, R. et al. High throughput single cell analysis of mitochondrial heteroplasmy in mitochondrial diseases. Sci. Rep. 10(1), 1\u201310 (2020).","journal-title":"Sci. Rep."},{"issue":"6382","key":"91142_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel, L. et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382), 1366\u20131370 (2018).","journal-title":"Science"},{"issue":"6285","key":"91142_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352(6285), 565\u2013569 (2016).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91142-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:13:44Z","timestamp":1670058824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91142-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91142"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91142-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.X.C. and L.Y.C. consult for NuProbe USA. D.Y.Z. declares a competing interest in the form of consulting for and equity ownership in NuProbe USA, Torus Biosystems, and Pana Bio. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11640"}}